Mark Fletcher

Mark Fletcher is a declared insider of Generex Biotechnology Corp, with filings sourced from SEC (Form 4). Over a trading history stretching from 17 August 2007 to 16 February 2016, the count stands at 14 filings.

The open-market side counts 7 purchases for €20k alongside 2 sales for €167k. The net balance comes to €147k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 share grant and 4 option exercises.

In size, the median ticket on the buying side is €3,136.

On 16 February 2016 came the latest disclosure, an option exercise in Generex Biotechnology Corp. The clock since the last published purchase (7 April 2011) now reads 5,694 days. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.